Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
THINK - diuretic-based blood pressure intensification in uncontrolled hypertension with chronic kidney disease
2022-501494-39-00Phase 3Authorised
- Sponsor
- CHRU Tours
- Start
- Jan 2023
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of indapamide, hydrochlorothiazide, furosemide and amiloride in hypertension (HTN) and chronic kidney disease (CKD) (2 arms), sponsored by CHRU Tours. Primary endpoint: Primary composite endpoint. Planned start Jan 2023; status: authorised.
02
Drugs
indapamidehydrochlorothiazidefurosemideamiloride
03
Conditions
hypertension (HTN)chronic kidney disease (CKD)
Beyond the preview
Go deeper on 2022-501494-39-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2022-501494-39-00.